抄録
CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, was administered to 14 patients with hyperlipidemia (7 of type IIa, 5 of type IIb and 2 of type III) 10mg a day for 12 weeks and the effects on serum lipids and apolipoproteins were investigated.
After 12 weeks of the drug treatment, serum total cholesterol, LDL-cholesterol and phospholipid were decreased significantly without lowering HDL-cholesterol level. Mean serum total cholesterol level was decreased by 20% (p<0.001). There were no effects on serum triglyceride, free fatty acid and lecithin-cholesterol acyltransferase activity.
Mean apolipoprotein A-I and A-II were increased by 13% (p<0.001, p<0.05) and mean apolipoprotein B was decreased by 17% (p<0.01). There were no effects on apolipoprotein C-II, C-III and E.
In patients with type III hyperlipidemia, CS-514 was less effective than in patients with type IIa and IIb. There were no major side effects.
These results suggested that CS-514 was effective to treat patients with type IIa and IIb hyperlipidemia.
